Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Apyx Medical (APYX) over the last 16 years, with Q3 2025 value amounting to $25.1 million.

  • Apyx Medical's Cash & Equivalents fell 1027.38% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year decrease of 1027.38%. This contributed to the annual value of $31.7 million for FY2024, which is 2728.63% down from last year.
  • According to the latest figures from Q3 2025, Apyx Medical's Cash & Equivalents is $25.1 million, which was down 1027.38% from $29.3 million recorded in Q2 2025.
  • Apyx Medical's 5-year Cash & Equivalents high stood at $43.7 million for Q4 2023, and its period low was $10.2 million during Q4 2022.
  • Its 5-year average for Cash & Equivalents is $27.5 million, with a median of $29.3 million in 2025.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 6698.41% in 2022, then skyrocketed by 32829.67% in 2023.
  • Apyx Medical's Cash & Equivalents (Quarter) stood at $30.9 million in 2021, then plummeted by 66.98% to $10.2 million in 2022, then surged by 328.3% to $43.7 million in 2023, then fell by 27.29% to $31.7 million in 2024, then fell by 20.81% to $25.1 million in 2025.
  • Its Cash & Equivalents stands at $25.1 million for Q3 2025, versus $29.3 million for Q2 2025 and $31.0 million for Q1 2025.